Short‐term efficacy of intravitreal aflibercept depending on subtypes of polypoidal choroidal vasculopathy: polypoidal choroidal neovascularization or idiopathic choroidal vasculopathy

• Published in: Acta ophthalmologica (Oxford, England) England), 2016-10, Vol.94 (S256), p.n/a
• Main Authors: Sagong, M., Jeong, S.
• Format: Article
• Language: English
• Subjects: Acuity; Ophthalmology; Vascular diseases; Vascularization; Visual acuity
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2016.0456

Purpose To compare the short‐term efficacy of intravitreal aflibercept treatment for polypoidal choroidal neovascularization (CNV) and idiopathic polypoidal choroidal vasculopathy (PCV). Methods Twenty‐nine patients (29 eyes) with treatment‐naïve subfoveal PCV were consecutively enrolled in this institutional study. The subjects were classified into two subtypes (type 1, polypoidal CNV, 16 eyes; and type 2, idiopathic PCV, 13 eyes) based on the presence or absence of both feeder and draining vessels on indocyanine green angiograph. Intravitreal aflibercept was administered at baseline and at 1, 2, and 4 months. The primary outcome was the polyp regression percentage after 3 monthly injections. Changes in the best‐corrected visual acuity and subfoveal choroidal thickness (CT) were evaluated at 3 and 6 months Results The complete polyp regression percentage was higher in type 1 than type 2 patients after 3 monthly injections (81 vs. 30%, respectively; p = 0.008). Type 1 patients showed better visual improvement at 3 months than type 2 patients (−0.34 vs. −0.08 logarithm of the minimum angle of resolution [logMAR], respectively; p = 0.050). Although subfoveal CT was significantly decreased after injections in both groups, type 2 patients with a thicker choroid at baseline showed a greater decrease than type 1 patients (−43.5 μm vs. −19.6 μm, respectively; p = 0.032) at 3 months. Conclusions There was a difference in early treatment response with aflibercept between two subtypes of PCV. Type 1 polypoidal CNV showed better visual improvement with a higher percentage of polyp regression than type 2 idiopathic PCV.